Discrimination of pancreatic cancer and pancreatitis by LC-MS metabolomics.

Lindahl, Anna; Heuchel, Rainer; Forshed, Jenny; Lehtiö, Janne; Löhr, Matthias; Nordström, Anders

Lindahl, Anna; Heuchel, Rainer; Forshed, Jenny; Lehtiö, Janne; Löhr, Matthias; Nordström, Anders.

Afiliación

Lindahl A; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Heuchel R; Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.
Forshed J; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Lehtiö J; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Löhr M; Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.
Nordström A; Department of Molecular Biology, Umeå University, 90187 Umeå, Sweden.

Metabolomics ; 13(5): 61, 2017.

Article en En | MEDLINE | ID: mdl-28413374

Palabras clave

Biomarkers; Discovery; LC-MS; Metabolism; Metabolomics; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Pancreatitis; Plasma; Serum; Validation

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Metabolomics Año: 2017 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google